Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Deals

Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round

Fineline Cube May 31, 2023

China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through...

Policy / Regulatory

Digital China Development Report Highlights Growth of Digital Healthcare Ecosystem

Fineline Cube May 31, 2023

The Cyberspace Administration of China (CAC) has released the Digital China Development Report (2022), providing...

Company Drug

BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia

Fineline Cube May 31, 2023

China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...

Company

Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D

Fineline Cube May 31, 2023

Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the...

Company Deals

XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services

Fineline Cube May 31, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...

Company Drug

Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments

Fineline Cube May 31, 2023

China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials

Fineline Cube May 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...

Company Deals

Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion

Fineline Cube May 31, 2023

US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which...

Company Drug

AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment

Fineline Cube May 30, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...

Company Deals

Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine

Fineline Cube May 30, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered...

Company Deals

Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China

Fineline Cube May 30, 2023

US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics,...

Company Deals

TYK Medicines Partners with WuXi STA for Comprehensive CMC Services

Fineline Cube May 30, 2023

Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...

Company Deals

Beijing’s E-Health Now Secures Tens of Millions in Series B Financing

Fineline Cube May 30, 2023

E-Health Now, a comprehensive health management platform headquartered in Beijing, has reportedly raised tens of...

Company Deals

Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO

Fineline Cube May 30, 2023

Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than...

Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Company Drug

Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval

Fineline Cube May 30, 2023

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

Fineline Cube May 30, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...

Company

Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology

Fineline Cube May 29, 2023

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...

Drug Policy / Regulatory

Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines

Fineline Cube May 29, 2023

The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans...

Company Drug

Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals

Fineline Cube May 29, 2023

China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...

Posts pagination

1 … 550 551 552 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.